Current Report Filing (8-k)
October 03 2018 - 4:48PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2018
Charles River Laboratories International, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
001-15943
|
|
06-1397316
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
251 Ballardvale St.
Wilmington, Massachusetts 01887
|
|
|
|
01887
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
Registrants Telephone Number, Including Area Code:
781-222-6000
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instructions A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On October 2, 2018, Craig B. Thompson informed the Board of Directors (the
Board
) of Charles River Laboratories International, Inc. (the
Company
) of his decision to resign, effective immediately, as a member of the Board. Dr. Thompsons resignation was not due to a
disagreement with the Company on any matter relating to the Companys operations, policies or practices.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Charles River Laboratories International, Inc.
|
|
|
|
|
Date: October 3, 2018
|
|
|
|
By:
|
|
/s/ Matthew Daniel
|
|
|
|
|
|
|
Name: Matthew Daniel
|
|
|
|
|
|
|
Title: Senior Corporate Vice President, Legal Compliance & Deputy General Counsel
|
3
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Sep 2023 to Sep 2024